Amendment No. 1 to Schedule 13D for NovaBay Pharmaceuticals, Inc.

This Amendment No. 1 to Schedule 13D, filed by R01 Fund LP and related entities, updates the ownership details of NovaBay Pharmaceuticals, Inc. The amendment reports the convertibility of Series D Non-Voting Convertible Preferred Stock following stockholder approval and the issuance of Series E Preferred Stock, which is convertible into 21,500,000 shares of Common Stock. The Reporting Persons collectively own 56,806,080 shares of Common Stock, representing approximately 45.1% of the outstanding shares. The amendment also includes details of a pre-funded warrant contract allowing the purchase of 2,702,703 shares of Common Stock, exercisable starting January 1, 2026, pending stockholder approval.